Pulmatrix, Inc. (PULM)

1.9903 -0.0297 (-1.44%) As of 11:29AM EDT. Market open.

Pulmatrix, Inc.

36 Crosby Drive
Suite 100
Bedford, MA 01730
United States
781 357 2333
https://www.pulmatrix.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 22

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Teofilo David Raad MBA	President, CEO & Director	577.72k	N/A	1970
Mr. Peter Ludlum CMA, MBA	Interim CFO and Principal Accounting & Financial Officer	510.22k	N/A	1955
Dr. Alexander M. Klibanov Ph.D.	Founder	N/A	N/A	1950

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine. It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates. The company was founded in 2003 and is headquartered in Bedford, Massachusetts.

Corporate governance

Pulmatrix, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.